ABSI stock forecast models are incorporating macroeconomic pressures, with biotech valuations likely to attract renewed interest as defensive plays in volatile markets. “With Prime on track to initiate IND-enabling activities for 1+ programs in its in vivo liver franchise and to nominate a DC in for RHO adRP in 2024, we believe the company is positioned for value inflection as it transitions from developing a collection of (interesting) science projects to advancing a product pipeline,” Livshits went on to say. This article Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside originally appeared on Benzinga.com ABSI stock forecast models from several Wall Street firms show a 12% upside potential over the next quarter if R&D milestones are met. Institutional buying trends have increased, pointing toward a possible momentum rally in the broader life sciences segment.
